| 1.445 -0.035 (-2.36%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.4 | 1-year : | 3.04 |
| Resists | First : | 2.05 | Second : | 2.6 |
| Pivot price | 1.56  |
|||
| Supports | First : | 1.16 | Second : | 0.97 |
| MAs | MA(5) : | 1.52 |
MA(20) : | 1.62 |
| MA(100) : | 2.58 |
MA(250) : | 4.58 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17.6 |
D(3) : | 29.8 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 7.73 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XAIR ] has closed above bottom band by 4.0%. Bollinger Bands are 69.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.41 - 1.42 | 1.42 - 1.43 |
| Close: | 1.43 - 1.44 | 1.44 - 1.46 |
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Wed, 22 Nov 2023
Beyond Air Inc (XAIR) Stock Is Down -1.73% This Week: Buy, Hold, or Sell? - InvestorsObserver
Tue, 14 Nov 2023
Beyond Air Inc Down 34.49% To $1.33 After Earnings Miss - InvestorsObserver
Tue, 14 Nov 2023
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday’s Mid-Day - Benzinga
Tue, 14 Nov 2023
Earnings call: Beyond Air Forecasts Robust Growth, Unveils Q2 2024 Operational Highlights and Financial Results By ... - Investing.com
Tue, 14 Nov 2023
Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Call Transcript - Yahoo Finance
Tue, 24 Oct 2023
I'm Antsy to Add Tons of Stocks, Including Remitly, ROIV and Beyond Air - RealMoney
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 2.646e+007 (%) |
| Held by Institutions | 16.4 (%) |
| Shares Short | 2,980 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.012e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 336.3 % |
| Return on Equity (ttm) | -54.9 % |
| Qtrly Rev. Growth | 298000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.54 |
| Dividend | 0 |
| Forward Dividend | 2.79e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|